Phio Pharmaceuticals

Coming – March 18

A Groundbreaking Approach To Treating Skin Cancer

Date and Time

March 18

–

4:00 PM ET / 1:00 PM PT

Details will be provided upon RSVP approval

About this Event

Phio Pharmaceuticals (NASDAQ: PHIO) has developed a unique approach to treating skin cancer.

At the core of Phio’s business is their INTASYL® siRNA technology designed to silence cancer-causing gene responses which directly suppress the body’s immune cells. Unlike many cancer drugs that flood the entire body, Phio’s lead program (PH-762) is only injected directly into the tumor. This dramatically improves patient safety and tolerability, virtually eliminating serious side effects typically seen with systemic immunotherapies.

What really stands out is the early promising clinical data in skin cancer, specifically in early stage cutaneous squamous cell carcinoma (cSCC). Some patients have shown complete or near-complete cancer clearance in a short timeframe, with no serious toxicities reported to date, in other words, a favorable safety profile. Significantly, there is no FDA-approved drug for early-stage cSCC which is the 2nd largest incidence of solid tumors—surgery is the default standard of care—presenting both a significant unmet need and market opportunity.

Phio has concluded the treatment phase of its Phase 1B trial and based on the data, is preparing to move into either Phase 2 or a Phase 2b/3 pivotal trial which would accelerate the path to commercialization.

Register today to hear from Phio CEO, Robert Bitterman, as he shares recent clinical progress, upcoming trial plans, and the company’s path toward accelerated development.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.